Long-term follow-up elderly patients locoregional breast cancer tamoxifen thirteen women years locoregional breast cancer tamoxifen primary treatment minimum years Complete response women partial response change progressive disease progressive disease patients initial response suitable conventional therapy actuarial survival rate cent patients cent initial complete response Seventy patients cent tamoxifen death recent follow-up Tamoxifen alternative treatment operable breast cancer women short term suitable concurrent disease unwilling surgery low morbidity rate tamoxifen need close follow-up medium long term sole primary treatment tamoxifen delays definitive therapy 